Physician profile
Stuart Hardy
NPI 1386608495
$4,823.05
in general payments reported to CMS, 2019-2025
26 companies · $911 in 2025
The $911 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,504 · 2020: $116 · 2021: $153 · 2022: $897 · 2023: $648 · 2024: $593 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.78 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,140.21 | 2019 | |
| Livanova USA, INC. | $701.19 | 2020-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Glaxosmithkline, LLC. | $569.19 | 2022-2025 | Nucala |
| Medtronic, INC. | $400.06 | 2023-2025 | Propel, Stealthstation S8 Platform |
| Genzyme Corporation | $357.88 | 2019-2025 | |
| Stryker Corporation | $314.18 | 2019-2025 | Audion Et Dilation System |
| Regeneron Healthcare Solutions, INC. | $257.97 | 2019-2025 | Dupixent |
| Acclarent, INC | $159.22 | 2022 | |
| Aerin Medical INC. | $154.45 | 2020-2025 | |
| Intersect Ent, INC. | $150.05 | 2019 | |
| Optinose US, INC. | $140.13 | 2019-2025 | |
| Amgen INC. | $128.41 | 2025 | Tezspire |
| Vertex Pharmaceuticals Incorporated | $47.41 | 2025 | |
| Phathom Pharmaceuticals, INC. | $34.94 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $34.45 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $31.19 | 2019 | |
| Integra Lifesciences Corporation | $29.29 | 2022 | |
| Smith+Nephew, INC. | $26.39 | 2022 | |
| Jubilant Hollisterstier LLC | $23.94 | 2023 | |
| Kaleo, INC. | $22.48 | 2021 | |
| Resmed Corp | $21.54 | 2024 | |
| Merck Sharp & Dohme LLC | $18.61 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $18.30 | 2023 | Seglentis |
| Astrazeneca Pharmaceuticals Lp | $14.27 | 2019 | |
| Greer Laboratories, INC. | $14.18 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.